

# International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature

JANET J. MAGUIRE, WILLIAM A. E. PARKER, STEVEN M. FOORD, TOM I. BONNER, RICHARD R. NEUBIG,  
 AND ANTHONY P. DAVENPORT

*Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (J.J.M., W.A.E.P., A.P.D.); GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, United Kingdom (S.M.F.); Laboratory of Genetics, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); and Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.)*

|   |   |
|---|---|
| Abstract . . . . .  | 1 |
| I. Introduction . . . . .   | 1 |
| II. Trace amine receptors . . . . .                                   | 2 |
| A. Designation of the trace amine 1 receptor . . . . .                | 2 |
| B. TAAR1 gene . . . . .   | 2 |
| C. Other family members . . . . .                                     | 2 |
| D. Phylogeny . . . . .  | 4 |
| III. Receptor structure . . . . .                                     | 4 |
| IV. Distribution of receptor and mRNA encoding the receptor . . . . . | 4 |
| V. Radiolabeled ligands . . . . .                                     | 5 |
| VI. Agonists . . . . .  | 5 |
| VII. Antagonists . . . . .  | 6 |
| VIII. Receptor signaling . . . . .                                    | 6 |
| IX. Physiological role . . . . .                                      | 7 |
| X. Pathophysiological role . . . . .                                  | 7 |
| XI. Genetically modified animals . . . . .                            | 7 |
| Acknowledgments . . . . .   | 7 |
| References . . . . .  | 7 |

**Abstract**—Trace amines such as *p*-tyramine and  $\beta$ -phenylethylamine are found endogenously as well as in the diet. Concomitant ingestion of these foodstuffs with monoamine oxidase inhibitors may result in the hypertensive crisis known as the “beer, wine, and cheese effect” attributed to their sympathomimetic action. Trace amines have been shown to act on one of a novel group of mammalian seven transmembrane spanning G protein-coupled receptors belonging to the rhodopsin superfamily, cloned in 2001. This receptor encoded by the human *TAAR1* gene is also present in rat and mouse genomes (*Taar1*) and has been shown to be activated by endogenous trace amine ligands, including *p*-tyramine and  $\beta$ -phenylethylamine. A number of drugs, most notably amphetamine and its derivatives, act as agonists at this receptor. This review proposes an official nomencla-

ture designating TAAR1 as the trace amine 1 receptor following the convention of naming receptors after the endogenous agonist, abbreviated to TA<sub>1</sub> where necessary. It goes on to discuss briefly the significance of the receptor, agents acting upon it, its distribution, and currently hypothesized physiological and pathophysiological roles. In humans, a further five genes are thought to encode functional receptors (*TAAR2*, *TAAR5*, *TAAR6*, *TAAR8*, and *TAAR9*). *TAAR3* seems to be a pseudogene in some individuals but not others. *TAAR4* is a pseudogene in humans, but occurs with *TAAR3* as a functional gene in rodents. Nine further genes are present in rats and mice. The endogenous ligands are not firmly established but some may respond to odorants consistent with their expression in olfactory epithelium.

## I. Introduction

Address correspondence to Dr. Anthony Davenport, NC-IUPHAR Emerging Pharmacology Group, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. E-mail: apd10@medschl.cam.ac.uk

This article is available online at <http://pharmrev.aspetjournals.org>.  
 doi:10.1124/pr.109.001107.

Trace amines, such as *p*-tyramine and  $\beta$ -phenylethylamine ( $\beta$ -PEA<sup>1</sup>) were discovered more than a century ago [e.g.,  $\beta$ -PEA by Nencki in 1876 (reviewed in Grandy, 2007)] and are well known sympathomimetics (Dale and Dixon, 1909; Barger and Dale, 1910) described as “false

transmitters.” In mammals, trace amines are synthesized from aromatic amino acids at rates comparable with classic monoamines (for example, tyramine from tyrosine, catalyzed by aromatic L-amino acid decarboxylase) (David et al., 1974; Boulton, 1976; Bowsher and Henry, 1983; Brier et al., 1991). However, they are detectable only at trace levels because they are substrates for monoamine oxidase and have a half-life of approximately 30 s (Durden and Philips, 1980; Paterson et al., 1990). Trace amines are also present in significant amounts in fermented foods (Chaytor et al., 1975; Hannah et al., 1988), and concomitant ingestion of these with monoamine oxidase inhibition may result in the hypertensive crisis known as the “beer, wine, and cheese effect” (Blackwell, 1963; Cooper, 1989; Caston et al., 2002).

In invertebrates, tyramine and octopamine are well characterized neurotransmitters, modulating metabolism and muscle tone (Axelrod and Saavedra, 1977; Roeder, 2005) via their own G protein coupled receptors, which have been cloned (Arakawa et al., 1990; Saudou et al., 1990).

## II. Trace Amine Receptors

### A. Designation of the Trace Amine 1 Receptor

In 2001, a novel mammalian G-protein-coupled receptor (GPCR) was cloned in a search for further subtypes of the 5HT receptor. It was shown to have high (nanomolar) affinity for trace amines and was therefore named the trace amine 1 (TA<sub>1</sub>) receptor (Borowsky et al., 2001). Subsequently, a family of genes encoding trace amine receptors was cloned (Borowsky et al., 2001; Lindemann et al., 2005) that showed closest homology to the aminergic receptors. The gene name was at first abbreviated to *TA* then *TAR* after the initial pairing. However, it was subsequently shown that not all family members may have high affinity for trace amines, which has led to the adoption of the nomenclature of “trace amine-associated receptors” (*TAARs*) for the genes encoding the receptors (Lindemann et al., 2005). The Human Genome Organization (HUGO) Gene Nomenclature Committee has approved the gene symbol for the trace amine receptor 1 as *TAAR1* ([http://www.genenames.org/cgi-bin/hgnc\\_search.pl](http://www.genenames.org/cgi-bin/hgnc_search.pl)) because it also avoids confusion with existing genes and ensures that this family has a unique name that can be searched on databases. This nomenclature links together the other members of the “Associated Receptors” that are homologous but for which the precise pharmacology remains to be determined.

To facilitate comparison between members of this family, current and previous nomenclatures for both the receptor proteins and the family of genes encoding them

are given in Table 1. To date, only one receptor, TA<sub>1</sub>, has been shown to respond to a cognate ligand, and several different groups replicated the results (Borowsky et al., 2001; Bunzow et al., 2001; Liberles and Buck, 2006), leading to the International Union of Pharmacology (IUPHAR)-recommended nomenclature for the receptor protein encoded by the gene *TAAR1* as trace amine receptor 1, abbreviated to TA<sub>1</sub>, first proposed by Borowsky et al. (2001). This follows the agreed convention on naming receptor proteins after the cognate endogenous ligand. According to IUPHAR convention no R is added to the abbreviated name for receptor proteins.

It has been shown that the rat TA<sub>1</sub> receptor, expressed in HEK293 cells, was also activated by thyronamines (decarboxylated and deiodinated metabolites of the thyroid hormones) (Scanlan et al., 2004; Hart et al., 2006) with a potency similar to that of tyramine (Bunzow et al., 2001). Cardiac effects of iodothyronamines have been reported in rat, but the rank order of potencies and affinities in ligand binding assays were not consistent with activation of TA<sub>1</sub> and led the authors to suggest that iodothyronamines might be acting at different trace amine-associated receptors (Frascarelli et al., 2008).

The main focus of this review is the recommendation of nomenclature for TA<sub>1</sub> receptors. For excellent, comprehensive reviews on trace amines, TA<sub>1</sub>, and the related family of receptors, see Grandy (2007), Zucchi et al. (2006), Lewin (2006), Lindemann and Hoener (2005), and Davenport (2003).

### B. TAAR1 Gene

*TAAR1* is localized in humans, along with genes for other trace amine-associated receptors, to a 109-kilobase region of chromosome 6q23.2 (Borowsky et al., 2001; Bunzow et al., 2001; Lindemann et al., 2005). *Taar* genes have also been found in the rat (Table 1; Bunzow et al., 2001) and mouse (Table 1; Borowsky et al., 2001). Designation of these genes follows the International Committee on Standardized Genetic Nomenclature for Mice and Rat Genome and Nomenclature Committee recommendation to use lower case italics (e.g., *Taar1*). This distinguishes the human gene, written in capitals, from those of rodents. The rat and mouse genes are localized to chromosomes 1p12 (Bunzow et al., 2001) and 10A3 (Borowsky et al., 2001; Reese et al., 2007), respectively.

### C. Other Family Members

The unofficial receptor names for the remaining receptors are included, for comparison, in Table 1 and await clear identification of their endogenous ligands, together with the official gene names. In humans, a further five genes are predicted to exist encoding trace amine-associated receptors [*TAAR2*, *TAAR5*, *TAAR6*, *TAAR8*, and *TAAR9* (Table 1)], and these are thought to be functional genes. *TAAR3* seems to be a pseudogene in some individuals but not others (Gloriam et al., 2005,

<sup>1</sup> Abbreviations:  $\beta$ -PEA,  $\beta$ -phenylethylamine; GPCR, G-protein coupled receptor; TA<sub>1</sub>, trace amine 1; IUPHAR, International Union of Pharmacology; HEK, human embryonic kidney.

TABLE 1  
Summary of human, mouse, and rat genes encoding trace amine and trace amine-associated receptors

| Receptor                                     | Human Gene    |              |  | Mouse Gene    |                        | Rat Gene      |                        |
|--|---------------|--------------|--|---------------|------------------------|---------------|------------------------|
|  | Old Name      | New Name     | Swiss Prot RefSeq                      | Name          | Swiss Prot RefSeq      | Name          | Swiss Prot RefSeq      |
| IUPHAR Receptor Nomenclature                 |               |              |  |               |                        |               |                        |
| TA <sub>1</sub>                              | <i>TAR1</i>   | <i>TAAR1</i> | Q96RJ0<br>NP_612200                    | <i>Taar1</i>  | Q923Y8<br>NP_444435    | <i>Taar1</i>  | Q923Y9<br>NP_599155    |
| Unofficial Receptor Terminology <sup>a</sup> |               |              |  |               |                        |               |                        |
| TA <sub>2</sub>                              |               |              |  | <i>Taar4</i>  | Q5QD15<br>NP_001008499 | <i>Taar4</i>  | Q923Y7<br>NP_783173    |
| TA <sub>3</sub>                              | <i>TAR3</i>   | <i>TAAR9</i> | Q96R19 <sup>b</sup><br>NP_778227       | <i>Taar9</i>  | Q5QD04<br>NP_001010831 | <i>Taar9</i>  | Q923Y6<br>NP_783192    |
| TA <sub>4</sub>                              | <i>TAR4</i>   | <i>TAAR6</i> | Q96R18 <sup>c</sup><br>NP_778237       | <i>Taar6</i>  | Q5QD13<br>NP_001010828 | <i>Taar6</i>  | Q923Y5<br>NP_783174    |
| TA <sub>5</sub>                              | <i>GPR102</i> | <i>TAAR8</i> | Q969N4<br>NP_444508                    |               |                        |               |                        |
| TA <sub>6</sub>                              |               |              |  |               |                        | <i>Taar7h</i> | Q923Y4<br>NP_783177    |
| TA <sub>7</sub>                              |               |              |  | <i>Taar8b</i> | Q5QD06<br>NP_001010837 | <i>Taar8b</i> | Q923Y3<br>NP_783191    |
| TA <sub>8</sub>                              |               |              |  | <i>Taar7a</i> | Q5QD12<br>NP_001010829 | <i>Taar7a</i> | Q923Y2<br>NP_783175    |
| TA <sub>9</sub>                              |               |              |  |               |                        | <i>Taar7g</i> | Q923Y1<br>NP_783178    |
| TA <sub>10</sub>                             |               |              |  | <i>Taar8c</i> | Q5QD05<br>NP_001010840 | <i>Taar8c</i> | Q923Y0<br>NP_783190    |
| TA <sub>11</sub>                             |               |              |  | <i>Taar8a</i> | Q5QD07<br>NP_001010830 | <i>Taar8a</i> | Q923X9<br>NP_783189    |
| TA <sub>12</sub>                             |               |              |  | <i>Taar7b</i> | Q5QD11<br>NP_001010827 | <i>Taar7b</i> | Q923X8<br>NP_783176    |
| TA <sub>13</sub>                             |               |              |  | <i>Taar7f</i> | Q5QD08<br>NP_001010839 | <i>Taar7f</i> | Pseudogene             |
| TA <sub>14</sub>                             |               |              |  | <i>Taar7e</i> | Q5QD09<br>NP_001010835 | <i>Taar7e</i> | Q923X6<br>NP_783180    |
| TA <sub>15</sub>                             |               |              |  | <i>Taar7d</i> | Q5QD10<br>NP_001010838 | <i>Taar7d</i> | Q923X5<br>NP_783181    |
| GPR57  |               |              |  | <i>Taar3</i>  | Q5QD16<br>NP_001008429 |               |                        |
| GPR58  | <i>GPR58</i>  | <i>TAAR2</i> | Q9P1P5<br>NP_001028252<br>or NP_055441 | <i>Taar2</i>  | Q5QD17<br>NP_001007267 | <i>Taar2</i>  | Q5QD25<br>NP_001008512 |
| PNR  | <i>PNR</i>    | <i>TAAR5</i> | O14804<br>NP_003958                    | <i>Taar5</i>  | Q5QD14<br>NP_001009574 | <i>Taar5</i>  | Q5QD23<br>NP_001009650 |

<sup>a</sup> Nomenclature as designated by Borowsky et al. (2001). See Lindemann and Hoener (2005) for further information on TAARs and Foord et al. (2005) and Schöneberg et al. (2007) for further information on pseudogenes.

<sup>b</sup> Stop codon present in 10% of humans.

<sup>c</sup> Polymorphisms in the human gene have been reported to be associated with schizophrenia and bipolar disorder (Duan et al., 2004; Pae et al., 2008a,b).

Vanti et al., 2003). *TAAR4* is a pseudogene in humans but occurs, with *TAAR3*, as a functional gene in rats and mice. Nine further genes are present in rats (Table 1; Bunzow et al., 2001) and mice (Table 1; Borowsky et al., 2001), but not in humans (Foord et al., 2005). The focus of this review is on human and rodent receptors; however, *TAAR* genes have also been reported in rhesus monkey (Miller et al., 2005) and avian (Mueller et al., 2008) genomes (Foord et al., 2005).

Odorants are detected in the nasal olfactory epithelium by the odorant receptor family, whose ~1000 members allow the discrimination of many different odorants. In a key article, Liberles and Buck (2006) reported the presence of trace amine-associated receptors that, like odorant receptors, are expressed in unique subsets of neurons dispersed in the mouse olfactory epithelium. Interestingly *Taar1* was not detected. They expressed some of the mouse *Taar* genes

in HEK293 cells linked to a fluorescent reporter and found that several responded to various amine ligands: 1) In agreement with previous reports for human and rat TA<sub>1</sub>, mouse TA<sub>1</sub> receptor recognized  $\beta$ -PEA with an EC<sub>50</sub> = 0.1  $\mu$ M (Liberles and Buck, 2006). 2) The mouse *Taar3* gene product responded to several primary amines, including isoamylamine (EC<sub>50</sub> = 10  $\mu$ M) and cyclohexylamine but, interestingly, not to the corresponding alcohols, isoamylalcohol and cyclohexanol, indicating slight variations in ligand structure eliminated ligand activity in some cases. 3) Mouse *Taar5* gene product (an ortholog also exists in humans; Table 1) responded to tertiary amines trimethylamine (EC<sub>50</sub> = 0.3  $\mu$ M) and *N*-methylpiperidine, but not to the related compounds methylamine, dimethylamine, and tetramethylammonium chloride. 4) Mouse *Taar7f* gene product responded to the tertiary amine, *N*-methylpiperidine (EC<sub>50</sub> = 20  $\mu$ M).

It is noteworthy that three of the ligands identified that activate mouse *Taar* gene products are natural components of mouse urine, a major source of social cues in rodents. Mouse *Taar4* gene product recognizes  $\beta$ -PEA, a compound whose elevation in urine is correlated with increases in stress and stress responses in both rodents and humans. The gene products of mouse *Taar3* and *Taar5* detected compounds (isoamylamine and trimethylamine, respectively) that are enriched in male versus female mouse urine. Isoamylamine in male urine is reported to act as a pheromone, accelerating puberty onset in female mice (Liberles and Buck, 2006). The authors suggest the *Taar* family has a chemosensory function that is distinct from odorant receptors, with a role associated with the detection of social cues. In mice, a clear discrepancy between the expression pattern of mRNA encoding *Taar1* and the other *Taar* family members has been confirmed by Regard et al. (2008). They have reported the anatomical distribution of mRNA for GPCRs in mouse tissues and shown highest expression of *Taar1* in pancreatic islets of Langerhans and white adipose with no evidence for expression in the olfactory epithelium, in contrast to the other family members that are relatively highly expressed in this tissue (Regard et al., 2008).

Human homologs of *Taar3*, *Taar4*, and *Taar7* are thought to be pseudogenes but *Taar5* does have an apparently functional human ortholog and the results suggest that functional members of the family more generally respond to trace amines. Responses were not reported for the gene products of other human orthologs *TAAR2*, *TAAR6*, *TAAR8*, and *TAAR9* (although it was not established that they were successfully expressed in HEK293 cells) and a role in humans for these TAARs is not yet clear.

#### D. Phylogeny

In addition to *Taar* genes being present in the rat (Table 1; Bunzow et al., 2001) and mouse (Table 1; Borowsky et al., 2001; Regard et al., 2008), they have also been reported in other species including rhesus monkey (Miller et al., 2005), avian (Mueller et al., 2008), fish, and amphibian genomes (Hashiguchi and Nishida, 2007) (see Foord et al., 2005).

The evolutionary pattern of the *TAAR* gene family is characterized by lineage-specific phylogenetic clustering (Gloriam et al., 2005; Lindemann et al., 2005; Hashiguchi and Nishida, 2007). These characteristics are very similar to those observed in the olfactory GPCRs and vomeronasal (V1R, V2R) GPCR gene families. Hashiguchi and Nishida (2007) carried out a careful phylogenetic analysis of the trace amine receptors in fish, amphibians, birds, and mammals and concluded (from the species they considered) that there are five types of trace amine receptor genes. The first type included expanded "trace amine-like" GPCR families within fish (fish can respond to catecholamines and their metabolites when

these are introduced into their water). However, type I also included the murine *Taar* receptors demonstrated to have an olfactory role and the human trace amine receptors, *TAAR5*, *TAAR6*, and *TAAR8*. Subfamily II also contained *Taar* genes that, in the mouse, are expressed in the olfactory epithelium and their products function as receptors for volatile amines (Liberles and Buck, 2006; Regard et al., 2008). Subfamilies III and V had no mammalian members. Subfamily IV contained human and murine *TAAR1* and *Taar1* genes, respectively. To date, these analyses suggest that the *TAAR1* gene alone encodes a trace amine receptor that may serve a nonsensory function. "Trace amine pharmacology" probably extends beyond the putative trace amine receptors. It will require further characterization using pharmacology and physiology to determine whether the trace amine receptors are "sensory" or not (Grandy, 2007).

### III. Receptor Structure

The human *TA<sub>1</sub>* receptor is a member of the rhodopsin-type superfamily (i.e., it is a class A GPCR), with 339 amino acids. It has a predicted seven transmembrane spanning domain structure with short *N*- and *C*-terminal domains of 23 to 49 and 27 to 33 amino acids, respectively (Lindemann et al., 2005). Rat and mouse *TA<sub>1</sub>* both have 332 amino acids, with sequence identities of 78 and 75% in relation to humans, respectively (see Table 2 and Figure 1).

### IV. Distribution of Receptor and mRNA Encoding the Receptor

In humans, reverse transcriptase polymerase chain reaction has shown moderate levels (~100 copies/ng of cDNA) of mRNA encoding *TA<sub>1</sub>* in the stomach; low levels (15–100 copies/ng of cDNA) in the amygdala, kidney, lung, and small intestine; and trace amounts (<15 copies/ng of cDNA) in the cerebellum, hippocampus, hypothalamus, liver, medulla oblongata, pituitary gland, pontine reticular formation, prostate gland, skeletal muscle, and spleen (Borowsky et al., 2001). Further amounts have been detected in pancreatic islets (Regard et al., 2007), circulating leukocytes of healthy subjects (D'Andrea et al., 2003; Nelson et al., 2007), and in normal small intestinal mucosal and endothelial cells (Kidd et al., 2008).

In mouse brain, mRNA encoding the receptor was detected by in situ hybridization in cerebellar Purkinje cells, trigeminal nuclei, olfactory bulb, hypothalamic nuclei, monoaminergic nuclei (such as the dorsal raphe and ventral tegmental area), amygdala, basal ganglia, cortex, and spinal cord (Borowsky et al., 2001). In peripheral tissues, mRNA encoding *Taar1* is reported in pancreatic islet and white adipose cells (Regard et al., 2008). Immunohistochemistry has shown *TA<sub>1</sub>* protein expres-



TABLE 2  
Classification of trace amine 1 receptor

| Receptor               | Trace Amine 1, TA <sub>1</sub>   |
|------------------------|--|
| Previous names         | TAR <sub>1</sub> , TRAR <sub>1</sub> , BO111, TAAR1 (approved human gene symbol)   |
| Structural information | 7TM<br>Human: 339 aa (SwissProt Q96RJ0), chr 6q23.2 (Entrez 134864)<br>Rat: 332 aa (SwissProt Q923Y9), chr 1p12 (Entrez 113914)<br>Mouse: 332 aa (SwissProt Q923Y8) chr 10A3 (Entrez 111174)   |
| Functional assays      | COS-7/HEK293 cells transfected with TA <sub>1</sub> and G $\alpha_s$ (Borowsky et al., 2001; Lindemann et al., 2005; Wolinsky et al., 2007); <i>X. laevis</i> oocytes cotransfected with TA <sub>1</sub> and CFTR (Borowsky et al., 2001); CHO cells expressing TA <sub>1</sub> and promiscuous G $\alpha_{16}$ (Navarro et al., 2006)   |
| Endogenous agonists    | Tyramine (pEC <sub>50</sub> = 6.4–6.7), $\beta$ -PEA (pEC <sub>50</sub> = 6.2–7.0), (Borowsky et al., 2001; Wainscott et al., 2007; Barak et al., 2008)  |
| Antagonists            | None currently commercially available  |
| Radioligand assays     | COS-7 cells transiently transfected with human TA <sub>1</sub> and rat G $\alpha_s$ (Borowsky et al., 2001)  |
| Radioligands           | [ <sup>3</sup> H]tyramine (pK <sub>D</sub> = 7.7) (Borowsky et al., 2001); [ <sup>125</sup> I]-[ <sup>2</sup> H]-, [ <sup>3</sup> H]3-iodothyronamine (Miyakawa and Scanlan, 2006)   |
| Transduction           | Couples to G $\alpha_s$ (Borowsky et al., 2001; Lindemann et al., 2005; Wolinsky et al., 2007) and G $\alpha_{16}$ (Navarro et al., 2006; Lewin et al., 2008) in vitro   |
| Receptor distribution  | Studies in humans, RT-PCR showed mRNA encoding TA <sub>1</sub> in stomach, amygdala, kidney, lung, small intestine, cerebellum, dorsal root ganglion, hippocampus, hypothalamus, liver, medulla, pancreas, pituitary, reticular formation, prostate, skeletal muscle, spleen (Borowsky et al., 2001), pancreatic islets (Regard et al., 2007), circulating leukocytes (D'Andrea et al., 2003), and intestinal mucosa/endothelium (Kidd et al., 2008); in rats, mRNA found in cardiac ventricles (Chiellini et al., 2007); in mice, in situ hybridization localized mRNA encoding TA <sub>1</sub> to discrete CNS areas, including the mitral cell layer of the olfactory bulb, trigeminal nuclei, cerebellar Purkinje cells, spinal cord, amygdala, hippocampus, monoaminergic nuclei (Borowsky et al., 2001), and dopaminergic neurons of the substantia nigra (Xie et al., 2007) |
| Tissue function        | Inhibits uptake and induces efflux of monoamines at striatal and thalamic synapses (Xie et al., 2008; Xie and Miller, 2008)  |

7TM, seven transmembrane; aa, amino acid(s); chr, chromosome; CFTR, cystic fibrosis transmembrane conductance regulator; CHO, Chinese hamster ovary; RT-PCR, reverse transcriptase polymerase chain reaction; CNS, central nervous system.

sion in the dopaminergic neurons of the substantia nigra (Xie et al., 2007).

In the rat, mRNA encoding TA<sub>1</sub> has been found in the cardiac ventricular wall (Chiellini et al., 2007). Bunzow et al. (2001) showed the subcellular localization of the rat TA<sub>1</sub> protein in a HEK293 expression system to be intracellular and punctate using immunocytochemistry. For experimental purposes, stable membrane expression of TA<sub>1</sub> has been achieved using a human-rat chimera, with a modified coding sequence including an influenza-derived hemagglutinin leader sequence and rat TA<sub>1</sub>-derived N and C termini and third intracellular loop (Lindemann et al., 2005) or by the generation of an *N*-glycosylated human TA<sub>1</sub> variant (Barak et al., 2008) that shows appropriate activation by  $\beta$ -PEA. The in vivo subcellular localization of TA<sub>1</sub> is yet to be confirmed.

## V. Radiolabeled Ligands

[<sup>3</sup>H]Tyramine (pK<sub>D</sub> = 7.7) has been available for a long time, but few studies have been carried out in expression systems of TA<sub>1</sub> (Borowsky et al., 2001). Radioactive thyronamines (e.g., [<sup>125</sup>I]3-iodothyronamine) have been synthesized (Miyakawa and Scanlan, 2006) but as yet are neither pharmacologically characterized nor commercially available.

## VI. Agonists

Endogenous trace amines act as agonists of the TA<sub>1</sub> receptor, for example *p*-tyramine and  $\beta$ -PEA (pEC<sub>50</sub> values at human receptor = 6.4–6.7, 6.2–7.0, respectively; Borowsky et al., 2001; Wainscott et al., 2007; Barak et al., 2008). In addition, the thyroid hormone derived thy-

ronamines [e.g., 3-iodothyronamine (T<sub>1</sub>AM); pEC<sub>50</sub> at rat receptor = 7.9; Scanlan et al., 2004; Hart et al., 2006] have affinity for TA<sub>1</sub>. In rat isolated perfused heart, trace amines and iodothyronamines are negative inotropic agents (Chiellini et al., 2007; Frascarelli et al., 2008), although the authors state that the rank order of agonist potency suggests that this is not a TA<sub>1</sub> response but may be mediated by a different trace amine-associated receptor, several of which are expressed in rat heart (Frascarelli et al., 2008).

Of the classic biogenic amines, only dopamine is reported to bind to expressed human TA<sub>1</sub> (K<sub>i</sub> 422 nM compared with 8 nM for  $\beta$ -PEA and 34 nM for tyramine; Borowsky et al., 2001) and produced functional responses in cAMP assays in expressed human and rodent receptors in the micromolar range (Borowsky et al., 2001; Bunzow et al., 2001). In these studies, noradrenaline, adrenaline, and serotonin had a negligible effect in both binding and functional assays. It is noteworthy that the rhesus monkey TA<sub>1</sub> receptor, which shows higher deduced amino acid sequence homology to the human receptor (96%) than do rodent receptors (<79% homology with human TA<sub>1</sub>) (Miller et al., 2005), responded to tyramine,  $\beta$ -PEA, octopamine, and tryptamine as expected (Miller et al., 2005; Xie and Miller, 2007) but also to comparable concentrations of dopamine, noradrenaline, and serotonin (Xie et al., 2007). The explanation and, indeed, the importance of this discrepancy is as yet unclear.

Exogenous agonists include amphetamine and its derivatives [e.g., *S*(+)-methamphetamine (pEC<sub>50</sub> at rat receptor = 6.1; Reese et al., 2007) and 3,4-methylenedioxymethamphetamine (pEC<sub>50</sub> at rat receptor =

|       |   |     |
|-------|---|-----|
| Rat   | -MHLCHNSANISHTNSNWSRDVRSALYSLISLIILTTLVGNLIVISISHFQQLHTPTNW                   | 59  |
| Mouse | -MHLCHAITNISHRNSDWSREVQASLYSLMSLIILATLVGNLIVISISHFQQLHTPTNW                   | 59  |
| Human | MMPFCHNIINISCVKNNWSNDVRSALYSLMVLIILTTLVGNLIVISISHFQQLHTPTNW                   | 60  |
|       | * : * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * |     |
| Rat   | LLHSMMAVVDFFLLGCLVMPYSMVRVVEHCWYFGELEFCKLHTSTDIMLSSASILHLAFISID               | 119 |
| Mouse | LLHSMMAIVDFFLLGCLIMPCSMVRTVERCWYFGEILCKVHTSTDIMLSSASIFHLAFISID                | 119 |
| Human | LIHSMATVDFFLLGCLVMPYSMVRSAEHCWYFGEVFCIKHTSTDIMLSSASIFHLAFISID                 | 120 |
|       | * : * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * |     |
| Rat   | RYAVCDPLRYKAKINLAATFVMILISWSLPAVFAFGMIFLELNLEGEELYHNQVFCRLR                   | 179 |
| Mouse | RYCAVCDPLRYKAKINISTILVMILVSWSLPAVFAFGMIFLELNLEGEELYRSQVSDLG                   | 179 |
| Human | RYAVCDPLRYKAKMNILVICVMIFISWSVPAVFAFGMIFLELNLEGEELYKHVHCRG                     | 180 |
|       | * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *     |     |
| Rat   | GCFPFFSKVSGVLAFTSFYIPGSVLMFVYYRIYFIAGQARSINRAN--LQVGLEGESR                    | 237 |
| Mouse | GCSFFSKVSGVLAFTSFYIPGSVLMFVYYRIYFIAGQARSINRTN--VQVGLEGKSQ                     | 237 |
| Human | GCSVFFSKISGVLTFTSFYIPGSIMLCVYYRIYLIAGQARLISDANQKLQIGLEMKNG                    | 240 |
|       | * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *     |     |
| Rat   | APQSKETKAAKTLGIMVGVFLCWCFFFCMVLDPLFGYVIPPTLNDTLNWFYGLNSAFN                    | 297 |
| Mouse | APQSKETKAAKTLGIMVGVFLCWCFFFCMVLDPLFGYVIPPTLNDALYWFYGLNSALN                    | 297 |
| Human | ISQSKERKAVKTLGIMVGVFLCWCFFFCITVMDPLFHYIIPPTLNDVLIWFYGLNSTFN                   | 300 |
|       | * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *     |     |
| Rat   | PMVYAFFYPWFERRALKMVLFGKIFQKDSSRSKLFL----                                      | 333 |
| Mouse | PMVYAFFYPWFERRALKMVLFGKIFQKDSSRSKLFL----                                      | 333 |
| Human | PMVYAFFYPWFRKALKMMLFGKIFQKDSSRCKLFLLELSS                                      | 339 |
|       | * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *     |     |

FIG. 1. Alignment of amino acid sequences of the rat, mouse, and human trace amine 1 (TA<sub>1</sub>) receptor. Produced using ClustalW2 (<http://www.uniprot.org/?tab=align>).

5.8; Bunzow et al., 2001]. Both amphetamine and methamphetamine seem to show a species-dependent stereoselectivity, at least in expression systems (Bunzow et al., 2001; Reese et al., 2007) (see Table 3 and Fig. 2).

## VII. Antagonists

There are no reports yet of fully characterized antagonists of the TA<sub>1</sub> receptor, and none are commercially available. Nonselective classical amine receptor antagonists have little TA<sub>1</sub> blocking ability (Wainscott et al., 2007). Tan et al. (2008) were able to rationally design and synthesize lead compounds, taking into account the recently described rotamer toggle switch model of GPCR

activation (Kobilka and Deupi, 2007; Rasmussen et al., 2007), concluding that a hexyloxy group and the outer or  $\beta$ -phenyl rings are essential for antagonism. It remains to be seen whether such compounds are specific and will become widely available in the near future.

## VIII. Receptor Signaling

TA<sub>1</sub> stably expressed in HEK293 or COS-7 cells has been shown to couple to G<sub>s</sub>, leading to intracellular cAMP accumulation (Borowsky et al., 2001; Lindemann et al., 2005; Wolinsky et al., 2007) and stimulation of the cystic fibrosis transmembrane conductance regulator in *Xenopus laevis* oocytes (Borowsky et al., 2001). In addition, TA<sub>1</sub> has been coupled to the promiscuous G $\alpha_{16}$  in Chinese hamster ovary cells, producing an increase in the intracellular Ca<sup>2+</sup> concentration as measured by fluorometry (Navarro et al., 2006; Lewin et al., 2008). Inhibitors of both protein kinases A and C have been shown to block TA<sub>1</sub>-mediated effects in synaptosomes (see section IX; Xie and Miller, 2007). In vivo signal transduction mechanisms are yet to be investigated.




FIG. 2. Examples of chemical structures of trace amine 1 (TA<sub>1</sub>) receptor endogenous and exogenous agonists.

TABLE 3

Selected agonists of the TA<sub>1</sub> receptor and reported species-specific  $pEC_{50}$  values

All values are for receptors in cell expression systems.

| Agonist                  | $pEC_{50}$ values  |                    |                    |
|--------------------------|--------------------|--------------------|--------------------|
|                          | Human              | Rat                | Mouse              |
| <i>p</i> -Tyramine       | 6.4 <sup>a</sup>   | 7.1 <sup>b</sup>   | 6.2 <sup>b</sup>   |
|                          | 6.5 <sup>c</sup>   | 7.2 <sup>d</sup>   | 7.1 <sup>e</sup>   |
|                          | 6.7 <sup>f</sup>   |                    |                    |
| $\beta$ -PEA             | 6.2 <sup>c</sup>   | 6.4 <sup>b</sup>   | 6.3 <sup>b</sup>   |
|                          | 6.5 <sup>f</sup>   | 6.6 <sup>d</sup>   | 7.4 <sup>e</sup>   |
|                          | 7.0 <sup>a,c</sup> |                    |                    |
| Octopamine               | 5.1 <sup>a</sup>   | 5.9 <sup>d</sup>   | 5.8 <sup>e</sup>   |
|                          | 5.4 <sup>f</sup>   |                    |                    |
|                          | 5.8 <sup>c</sup>   |                    |                    |
| 3-Iodothyronamine        | No data            | 7.9 <sup>g,h</sup> | 7.0 <sup>g,h</sup> |
| <i>S</i> (+)-Amphetamine | 6.0 <sup>c</sup>   | 6.1 <sup>b</sup>   | 6.7 <sup>b</sup>   |
|                          | 6.9 <sup>c</sup>   | 6.4 <sup>d</sup>   | 8.7 <sup>e</sup>   |
| <i>R</i> (-)-Amphetamine | 6.6 <sup>c</sup>   | 6.5 <sup>b</sup>   | 5.3 <sup>b</sup>   |
|                          |                    | 6.7 <sup>d</sup>   | 7.2 <sup>e</sup>   |

<sup>a</sup> Wainscott et al. (2007).

<sup>b</sup> Reese et al. (2007).

<sup>c</sup> Barak et al. (2008).

<sup>d</sup> Bunzow et al. (2001).

<sup>e</sup> Wolinsky et al. (2007).

<sup>f</sup> Borowsky et al. (2001).

<sup>g</sup> Scanlan et al. (2004).

<sup>h</sup> Hart et al. (2006).

## IX. Physiological Role

Levels of trace amines have been measured in human plasma and are in the low nanomolar range (for example, see Zhou et al., 2001; D'Andrea et al., 2003). Tyramine and  $\beta$ -PEA have  $pK_i$  values for human  $TA_1$  of 8.1 and 7.5, respectively (Borowsky et al., 2001) with  $pEC_{50}$  values in the high nanomolar range (6.2–7.0; Table 3). For comparison, the biogenic amines noradrenaline and adrenaline circulate at similar low nanomolar concentrations (Goldstein et al., 2003) but are functional at higher concentrations, with  $pK_i$  of 6.0 to 6.5 for  $\alpha_1$ - and  $\beta_1$ -adrenergic receptors and  $pEC_{50}$  values again in the high nanomolar range (NC-IUPHAR GPCR database: <http://www.iuphar-db.org/GPCR/ReceptorFamiliesForward>). Selective  $TA_1$  antagonists have not yet been developed but are required to confirm the precise physiology of this receptor system.

The role of the  $TA_1$  receptor is most understood in the central nervous system, where it is believed to modulate monoaminergic neurotransmission, thus affecting a number of neural networks and processes.  $\beta$ -PEA inhibits uptake and induces efflux of dopamine and serotonin in striatal synaptosomes and of norepinephrine in thalamic synaptosomes in vitro by interacting with transporters, for example the dopamine transporter (Xie and Miller, 2007, 2008; Xie et al., 2008). The effect is abolished in the  $TA_1$  knockout (Lindemann et al., 2008; Xie and Miller, 2008; Xie et al., 2008) and by inhibitors of protein kinases A and C (Xie and Miller, 2007). In addition,  $TA_1$  may be immunomodulatory, because mRNA encoding the receptor is up-regulated in circulating leukocytes after administration of the mitogen phytohemagglutinin (Nelson et al., 2007). Trace amines,  $\beta$ -PEA in particular, have long been associated with sustaining mood (Fischer and Heller, 1972; Sabelli and Mosnaim, 1974; Boulton, 1980), although a specific role for  $TA_1$  in this has yet to be elucidated. The effect of genetically disrupting synthesis of the endogenous agonists tyramine and  $\beta$ -PEA has not been assessed.

## X. Pathophysiological Role

Large increases in plasma trace amine levels can occur in patients or animals on monoamine oxidase inhibitors, and alterations in levels have been reported in some diseases. The  $TA_1$  receptor has not been directly linked with any pathophysiological process, although trace amines are known to be associated with the hypertensive “beer, wine, and cheese effect” and are thought to play a role in psychiatric disorders such as schizophrenia (O'Reilly et al., 1991) and depression (Boulton, 1980; Premont et al., 2001) as well as primary headache (D'Andrea et al., 2004). Modulation of trace amine systems may be a potential therapeutic avenue (Branchek and Blackburn, 2003; Berry, 2007), particularly because the receptors are likely to be amenable as drug targets (Davenport, 2003). Linkage analysis has also shown a

correlation between schizophrenia and polymorphisms in the chromosomal region encoding the trace amine-associated receptors (Levi et al., 2005; Pae et al., 2008a,b) but not  $TA_1$ , polymorphisms of which are yet to be reported.

## XI. Genetically Modified Animals

Deletion of the *Taar1* gene in mice results in viable, fertile animals. They exhibit a phenotype characterized by minor spontaneous hyperactivity, reduced prepulse inhibition, increased sensitization to the psychomotor-stimulatory effects of amphetamine, raised levels of dopamine and norepinephrine in the dorsal striatum, increased striatal  $D_2$  receptor expression, and an elevated spontaneous firing rate of dopaminergic neurons in the ventral tegmental area compared with the wild type (Wolinsky et al., 2007; Sotnikova et al., 2008; Xie and Miller, 2008; Xie et al., 2008). This phenotype has been proposed as an animal model of schizophrenia (Wolinsky et al., 2007) and also as hemi-Parkinsonian (Sotnikova et al., 2008). In addition, in  $TA_1$ -deficient mice,  $\beta$ -PEA was unable to modify the uptake or efflux of classic amine transmitters in striatal or thalamic synaptosomes as had been shown for wild type (Xie and Miller, 2008; Xie et al., 2008). The effect of genetically disrupting synthesis of the endogenous agonists tyramine and  $\beta$ -PEA has not been assessed, although because these compounds are also metabolites, they cannot readily be disrupted-out without identifying enzymes exclusive to their production.

**Acknowledgments.** This work was supported by British Heart Foundation [Grants PS/02/001, PG/05/127/19872]; and by the Intramural Research Program of the National Institutes of Health National Institute of Mental Health.

## REFERENCES

- Arakawa S, Gocayne JD, McCombie WR, Urquhart DA, Hall LM, Fraser CM, and Venter JC (1990) Cloning, localization, and permanent expression of a *Drosophila* octopamine receptor. *Neuron* **4**:343–354.
- Axelrod J and Saavedra JM (1977) Octopamine. *Nature* **265**:501–504.
- Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, Violin JD, Lefkowitz RJ, Caron MG, and Gainetdinov RR (2008) Pharmacological characterization of membrane-expressed human trace amine associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer (BRET) cAMP biosensor. *Mol Pharmacol* **74**:585–594.
- Barger G and Dale HH (1910) Chemical structure and sympathomimetic action of amines. *J Physiol* **41**:19–59.
- Berry MD (2007) The potential of trace amines and their receptors for treating neurological and psychiatric diseases. *Rev Recent Clin Trials* **2**:3–19.
- Blackwell B (1963) Hypertensive crisis due to monoamine-oxidase inhibitors. *Lancet* **26**:849–850.
- Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhilani PP, Bonini JA, Pathirana S, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. *Proc Natl Acad Sci U S A* **98**:8966–8971.
- Boulton AA (1976) Identification, distribution, metabolism, and function of meta and para tyramine, phenylethylamine and tryptamine in brain. *Adv Biochem Psychopharmacol* **15**:57–67.
- Boulton AA (1980) Trace amines and mental disorders. *Can J Neurol Sci* **7**:261–263.
- Bowsher RR and Henry DP (1983) Decarboxylation of p-tyrosine: a potential source of p-tyramine in mammalian tissues. *J Neurochem* **40**:992–1002.
- Branchek TA and Blackburn TP (2003) Trace amine receptors as targets for novel therapeutics: legend, myth and fact. *Curr Opin Pharmacol* **3**:90–97.
- Brier ME, Bowsher RR, Mayer PR, and Henry DP (1991) Conversion of p-tyrosine to p-tyramine in the isolated perfused rat kidney: modulation by perfusate concentrations of p-tyrosine. *Life Sci* **48**:901–907.
- Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, et al. (2001) Amphetamine,



- 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. *Mol Pharmacol* **60**:1181–1188.
- Caston JC, Eaton CL, Gheorghiu BP, and Ware LL (2002) Tyramine induced hyper-tensive episodes and panic attacks in hereditary deficient monoamine oxidase patients: case reports. *J S C Med Assoc* **98**:187–192.
- Chaytor JP, Crathorne B, and Saxby MJ (1975) The identification and significance of 2-phenylethylamine in foods. *J Sci Food Agric* **26**:593–598.
- Chiellini G, Frascarelli S, Ghelardoni S, Carnicelli V, Tobias SC, DeBarber A, Brogioni S, Ronca-Testoni S, Cerbai E, Grandy DK, et al. (2007) Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. *FASEB J* **21**:1597–1608.
- Cooper AJ (1989) Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. *Br J Psychiatry Suppl* **6**:38–45.
- Dale HH and Dixon WE (1909) The action of pressor amines produced by putrefaction. *J Physiol* **39**:25–44.
- D'Andrea G, Terrazzino S, Fortin D, Farruggio A, Rinaldi L, and Leon A (2003) HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes. *Neurosci Lett* **346**:89–92.
- D'Andrea G, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, and Bussone G (2004) Elevated levels of circulating trace amines in primary headaches. *Neurology* **62**:1701–1705.
- Davenport AP (2003) Peptide and trace amine orphan receptors: prospects for new therapeutic targets. *Curr Opin Pharmacol* **3**:127–134.
- David JC, Dairman W, and Udenfriend S (1974) Decarboxylation to tyramine: a major route of tyrosine metabolism in mammals. *Proc Natl Acad Sci U S A* **71**:1771–1775.
- Duan J, Martinez M, Sanders AR, Hou C, Saitou N, Kitano T, Mowry BJ, Crowe RR, Silverman JM, Levinson DF, et al. (2004) Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. *Am J Hum Genet* **75**:624–638.
- Durden DA and Philips SR (1980) Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain. *J Neurochem* **34**:1725–1732.
- Fischer E and Heller B (1972) Phenylethylamine as a neurohumoral agent in brain. *Behav Neuropsychiatry* **4**:8–11.
- Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M, and Harmar AJ (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacol Rev* **57**:279–288.
- Frascarelli S, Ghelardoni S, Chiellini G, Vargiu R, Ronca-Testoni S, Scanlan TS, Grandy DK, and Zucchi R (2008) Cardiac effects of trace amines: pharmacological characterization of trace amine-associated receptors. *Eur J Pharmacol* **587**:231–236.
- Gloriam DE, Bjarnadottir TK, Schiöth HB, and Fredriksson R (2005) High species variation within the repertoire of trace amine receptors. *Ann N Y Acad Sci* **1040**:323–327.
- Goldstein DS, Eisenhofer G, and Kopin IJ (2003) Sources and significance of plasma levels of catechols and their metabolites in humans. *J Pharmacol Exp Ther* **305**:800–811.
- Grandy DK (2007) Trace amine-associated receptor 1: family archetype or iconoclast? *Pharmacol Ther* **116**:355–390.
- Hannah P, Glover V, and Sandler M (1988) Tyramine in wine and beer. *Lancet* **1**:879.
- Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK, and Scanlan TS (2006) Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. *J Med Chem* **49**:1101–1112.
- Hashiguchi Y and Nishida M (2007) Evolution of trace amine associated receptor (TAAR) gene family in vertebrates: lineage-specific expansions and degradations of a second class of vertebrate chemosensory receptors expressed in the olfactory epithelium. *Mol Biol Evol* **24**:2099–2107.
- Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, and Pfragner R (2008) The luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants and olfactants. *Am J Physiol Gastrointest Liver Physiol* **295**:G260–G272.
- Kobilka BK and Deupi X (2007) Conformational complexity of G-protein-coupled receptors. *Trends Pharmacol Sci* **28**:397–406.
- Levi A, Kohn Y, Kanyas K, Amann D, Pae CU, Hamdan A, Segman RH, Avidan N, Karni O, Korner M, et al. (2005) Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: increased evidence for linkage and reduced linkage interval. *Eur J Hum Genet* **13**:763–771.
- Lewin AH (2006) Receptors of mammalian trace amines. *AAPS J* **8**:E138–E145.
- Lewin AH, Navarro HA, and Mascarella SW (2008) Structure-activity correlations for beta-phenylethylamines at human trace amine receptor 1. *Bioorg Med Chem* **16**:7415–7423.
- Liberles SD and Buck LB (2006) A second class of chemosensory receptors in the olfactory epithelium. *Nature* **442**:645–650.
- Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, and Hoener MC (2005) Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. *Genomics* **85**:372–385.
- Lindemann L and Hoener MC (2005) A renaissance in trace amines inspired by a novel GPCR family. *Trends Pharmacol Sci* **26**:274–281.
- Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluthmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, et al. (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. *J Pharmacol Exp Ther* **324**:948–956.
- Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, and Madras BK (2005) Primate trace amine receptor 1 modulation by the dopamine transporter. *J Pharmacol Exp Ther* **313**:983–994.
- Miyakawa M and Scanlan TS (2006) Synthesis of [<sup>125</sup>I]-, [<sup>2</sup>H]-, and [<sup>3</sup>H]-labeled 3-iodothyronamine (T1AM). *Synth Commun* **36**:891–902.
- Mueller JC, Steiger S, Fidler AE, and Kempnaers B (2008) Biogenic Trace Amine-Associated Receptors (TAARs) are encoded in avian genomes: evidence and possible implications. *J Hered* **99**:174–176.
- Navarro HA, Gilmour BP, and Lewin AH (2006) A rapid functional assay for the human trace amine-associated receptor 1 based on the mobilization of internal calcium. *J Biomol Screen* **11**:688–693.
- Nelson DA, Tolbert MD, Singh SJ, and Bost KL (2007) Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes. *J Neuroimmunol* **192**:21–30.
- O'Reilly R, Davis BA, Durden DA, Thorpe L, Machnee H, and Boulton AA (1991) Plasma phenylethylamine in schizophrenic patients. *Biol Psychiatry* **30**:145–150.
- Pae CU, Yu HS, Amann D, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Patkar AA, et al. (2008a) Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. *J Psychiatr Res* **42**:35–40.
- Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, Lee C, Mandelli L, De Ronchi D, Paik IH, and Serretti A (2008b) TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study. *Eur Psychiatry* **23**:390–395.
- Paterson IA, Juorio AV, and Boulton AA (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? *J Neurochem* **55**:1827–1837.
- Premont RT, Gainetdinov RR, and Caron MG (2001) Following the trace of elusive amines. *Proc Natl Acad Sci U S A* **98**:9474–9475.
- Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Fian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, et al. (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. *Nature* **450**:383–387.
- Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, and Grandy DK (2007) Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. *J Pharmacol Exp Ther* **321**:178–186.
- Regard JB, Kataoka H, Cano DA, Camerer E, Yin L, Zheng YW, Scanlan TS, Hebrok M, and Coughlin SR (2007) Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. *J Clin Invest* **117**:4034–4043.
- Regard JB, Sato IT, and Coughlin SR (2008) Anatomical profiling of G protein-coupled receptor expression. *Cell* **135**:561–571.
- Roeder T (2005) Tyramine and octopamine: ruling behavior and metabolism. *Annu Rev Entomol* **50**:447–477.
- Sabelli HC and Moshaim AD (1974) Phenylethylamine hypothesis of affective behavior. *Am J Psychiatry* **131**:695–699.
- Saudou F, Amlaiki N, Plassat JL, Borrelli E, and Hen R (1990) Cloning and characterization of a Drosophila tyramine receptor. *EMBO J* **9**:3611–3617.
- Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruczich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, et al. (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. *Nat Med* **10**:638–642.
- Schöneberg T, Hofreiter M, Schulz A, and Römpler H (2007) Learning from the past: evolution of GPCR functions. *Trends Pharmacol Sci* **28**:117–121.
- Sotnikova TD, Zorina OI, Ghisi V, Caron MG, and Gainetdinov RR (2008) Trace amine associated receptor 1 and movement control. *Parkinsonism Relat Disord* **14**(Suppl 2):S99–S102.
- Tan ES, Groban ES, Jacobson MP, and Scanlan TS (2008) Toward deciphering the code to aminergic G protein-coupled receptor drug design. *Chem Biol* **15**:343–353.
- Vanti WB, Muglia P, Nguyen T, Cheng R, Kennedy JL, George SR, and O'Dowd BF (2003) Discovery of a null mutation in a human trace amine receptor gene. *Genomics* **82**:531–536.
- Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, and Nelson DL (2007) Pharmacological characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. *J Pharmacol Exp Ther* **320**:475–485.
- Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, and Gerald CP (2007) The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. *Genes Brain Behav* **6**:628–639.
- Xie Z and Miller GM (2007) Trace amine-associated receptor 1 is a modulator of the dopamine transporter. *J Pharmacol Exp Ther* **321**:128–136.
- Xie Z and Miller GM (2008)  $\beta$ -phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. *J Pharmacol Exp Ther* **325**:617–628.
- Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, and Miller GM (2007) Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. *J Pharmacol Exp Ther* **321**:116–127.
- Xie Z, Westmoreland SV, and Miller GM (2008) Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. *J Pharmacol Exp Ther* **325**:629–640.
- Zhou G, Miura Y, Shoji H, Yamada S, and Matsuishi T (2001) Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. *J Neurol Neurosurg Psychiatry* **70**:229–231.
- Zucchi R, Chiellini G, Scanlan TS, and Grandy DK (2006) Trace amine-associated receptors and their ligands. *Br J Pharmacol* **149**:967–978.